Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial

Abstract

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer

“…All model patients began from the PFS health state and were randomly assigned to two first-line treatments. According to the safety data reported in clinical trials, we considered that the model patients with the PFS health state may discontinue first-line therapies because of the occurrence of adverse events (AEs) ( Zhou et al, 2015 ; Shi et al, 2021 ). Therefore, the PFS health state was divided into two substates: PFS health state while receiving first-line therapy and PFS health state with first-line therapy discontinued.…”

“…Figure 1 illustrates the possible transitions between different health states. Patients with disease progression during the first-line treatment would enter the PD health state, in which a certain proportion of patients continue to receive subsequent anticancer therapy if they obtained sustained benefits, otherwise they were recommended to best supportive care (BSC) ( Guidelines Working Committee of Chinese society of Clinical Oncology, 2020 ; Shi et al, 2021 ). To reflect the clinical practice in real-life scenarios, patients were proceeded to palliative care before death.…”

“…From the perspective of the Chinese healthcare system, two economic evaluations found that bevacizumab combined with chemotherapy was not cost-effective among patients with advanced nonsquamous NSCLC when compared with conventional chemotherapy ( Zheng et al, 2018 ; Li et al, 2019 ). Since cancer is now a leading cause of premature death and has imposed a substantial economic burden on the national health system, the Chinese government has been engaged in sponsoring local scientists to develop bevacizumab biosimilar agents in recent years ( Han et al, 2019 ; Yang et al, 2019 ; Shi et al, 2021 ). Bevacizumab biosimilars have shown similar benefits to the bevacizumab originator at a lower price, which could increase patients’ affordability and access to the treatment ( National Medical Products Administration, 2019 ).…”

“…LY01008 is a bevacizumab biosimilar developed by Boan Biotechnology Co., Ltd. (Yantai, Shandong, China). LY01008 in combination with platinum-based chemotherapy was approved for use based on the result of a phase III clinical trial that demonstrated the similar therapeutic benefit of LY01008 to the bevacizumab originator as first-line therapy in Chinese patients with advanced or recurrent nonsquamous NSCLC ( Shi et al, 2021 ). The development of bevacizumab biosimilars has made a considerable impact on the Chinese healthcare system, given the huge beneficiary population.…”

Mesenchymal stem cells: ideal seeds for treating diseases

“…Angiogenesis is a common and important physiological or pathological behavior during the growth of solid tumors [94,95]. MSCs can secrete a variety of proangiogenic factors.…”